[The effect of low doses of nakom on the hormonal secretion of the hypothalamo-hypophyseal-adrenal system in patients with infantile cerebral palsy].
The levels of hormones of hypothalamo-hypophyseal-adrenal system were measured in 14 10-14 year old children with infantile cerebral paralysis (ICP) with central catecholaminergic motor insufficiency. Contents of adrenocorticotropic hormone (ACTH), hydrocortisone (HC), somatotropic hormone, prolactin (P) were examined before and during Nacome administration (62.5 mg once daily in the morning). 110 patients of the same age with ICP and 18 children with acquired encephalopathy (EP) formed the control group. The elevations of ACTH, HC and P were revealed in spastic forms of ICP. Meanwhile nearly normal hormonal levels were observed in hyperkinetic forms of ICP and EP. The more pronounced effect was noted in "dopamine-dependent" children in which the drug's administration resulted in normalization of clinical and biochemical indices. Hyperkinetic phenomena revealed the connection between the character of neuromotor dyskinesias and the state of hypothalamo-hypophyseal-adrenal axis which is regulated by dopamine. The data obtained show hypofunction of dopaminergic neurotransmitter cerebral systems in patients with ICP that plays important pathogenetic role in development of disease with systemic manifestations.
Brin
I L
IL
Mashilov
K V
KV
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000097:blood / Q000378:metabolism*; D002230:Carbidopa / Q000008:administration & dosage* / Q000494:pharmacology; D002547:Cerebral Palsy / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007028:Hypothalamic Hormones / Q000097:blood / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000378:metabolism; D007980:Levodopa / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D010907:Pituitary Hormones / Q000097:blood / Q000378:metabolism*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D018491:Dopamine Agonists; D004338:Drug Combinations; D007028:Hypothalamic Hormones; D010907:Pituitary Hormones; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa